# | Title | Journal | Year | Citations |
---|
1 | Hepatocellular carcinoma: a review | Journal of Hepatocellular Carcinoma | 2016 | 842 |
2 | Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance | Journal of Hepatocellular Carcinoma | 2018 | 155 |
3 | <p>LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance</p> | Journal of Hepatocellular Carcinoma | 2019 | 93 |
4 | Hepatocellular carcinoma: epidemiology and risk factors | Journal of Hepatocellular Carcinoma | 2014 | 88 |
5 | Combined hepatocellular cholangiocarcinoma (cHCC-CC): an update of genetics, molecular biology, and therapeutic interventions | Journal of Hepatocellular Carcinoma | 2019 | 83 |
6 | The Mechanisms of HBV-Induced Hepatocellular Carcinoma | Journal of Hepatocellular Carcinoma | 2021 | 83 |
7 | Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study | Journal of Hepatocellular Carcinoma | 2021 | 71 |
8 | Wnt/β-Catenin Signaling as a Driver of Hepatocellular Carcinoma Progression: An Emphasis on Molecular Pathways | Journal of Hepatocellular Carcinoma | 2021 | 65 |
9 | <p>The Immune Modulation Effect of Locoregional Therapies and Its Potential Synergy with Immunotherapy in Hepatocellular Carcinoma</p> | Journal of Hepatocellular Carcinoma | 2020 | 64 |
10 | GPC-3 in hepatocellular carcinoma: current perspectives | Journal of Hepatocellular Carcinoma | 2016 | 62 |
11 | Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options | Journal of Hepatocellular Carcinoma | 2021 | 62 |
12 | Hepatocellular carcinoma: early-stage management challenges | Journal of Hepatocellular Carcinoma | 2017 | 60 |
13 | <p>Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment</p> | Journal of Hepatocellular Carcinoma | 2020 | 60 |
14 | Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies | Journal of Hepatocellular Carcinoma | 2017 | 58 |
15 | Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review | Journal of Hepatocellular Carcinoma | 2017 | 56 |
16 | <p>Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date</p> | Journal of Hepatocellular Carcinoma | 2019 | 55 |
17 | <p>Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives</p> | Journal of Hepatocellular Carcinoma | 2019 | 54 |
18 | Pretreatment neutrophil–lymphocyte ratio: useful prognostic biomarker in hepatocellular carcinoma | Journal of Hepatocellular Carcinoma | 2018 | 53 |
19 | Pediatric hepatocellular carcinoma: challenges and solutions | Journal of Hepatocellular Carcinoma | 2017 | 49 |
20 | Liver Imaging Reporting and Data System: an expert consensus statement | Journal of Hepatocellular Carcinoma | 2017 | 46 |
21 | Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions | Journal of Hepatocellular Carcinoma | 2017 | 45 |
22 | Hepatocellular carcinoma: a review of diagnostic challenges for the pathologist | Journal of Hepatocellular Carcinoma | 2018 | 44 |
23 | <p>Angiogenesis in Hepatocellular Carcinoma; Pathophysiology, Targeted Therapy, and Role of Imaging</p> | Journal of Hepatocellular Carcinoma | 2020 | 44 |
24 | The Crosstalk Between Cancer Cells and Neutrophils Enhances Hepatocellular Carcinoma Metastasis via Neutrophil Extracellular Traps-Associated Cathepsin G Component: A Potential Therapeutic Target | Journal of Hepatocellular Carcinoma | 2021 | 43 |
25 | <p>Experimental Study of Hepatocellular Carcinoma Treatment by Shikonin Through Regulating PKM2</p> | Journal of Hepatocellular Carcinoma | 2020 | 41 |
26 | Irreversible electroporation of hepatocellular carcinoma: patient selection and perspectives | Journal of Hepatocellular Carcinoma | 2017 | 40 |
27 | The androgen receptor as an emerging target in hepatocellular carcinoma | Journal of Hepatocellular Carcinoma | 2015 | 39 |
28 | Fibrolamellar hepatocellular carcinoma: current clinical perspectives | Journal of Hepatocellular Carcinoma | 2015 | 39 |
29 | Hepatocellular carcinoma in elderly patients: challenges and solutions | Journal of Hepatocellular Carcinoma | 2016 | 36 |
30 | NAFLD-Associated HCC: Progress and Opportunities | Journal of Hepatocellular Carcinoma | 2021 | 33 |
31 | Transarterial radioembolization for hepatocellular carcinoma: a review | Journal of Hepatocellular Carcinoma | 2016 | 32 |
32 | Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma | Journal of Hepatocellular Carcinoma | 2016 | 32 |
33 | <p>Development and Verification of the Hypoxia-Related and Immune-Associated Prognosis Signature for Hepatocellular Carcinoma</p> | Journal of Hepatocellular Carcinoma | 2020 | 31 |
34 | Anti-PD-1 Immunotherapy Improves the Efficacy of Hepatic Artery Infusion Chemotherapy in Advanced Hepatocellular Carcinoma | Journal of Hepatocellular Carcinoma | 2021 | 30 |
35 | Emerging role of Toll-like receptor 4 in hepatocellular carcinoma | Journal of Hepatocellular Carcinoma | 2015 | 29 |
36 | <p>Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date</p> | Journal of Hepatocellular Carcinoma | 2020 | 29 |
37 | Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions | Journal of Hepatocellular Carcinoma | 2021 | 29 |
38 | Albumin-Bilirubin (ALBI) and Monocyte to Lymphocyte Ratio (MLR)-Based Nomogram Model to Predict Tumor Recurrence of AFP-Negative Hepatocellular Carcinoma | Journal of Hepatocellular Carcinoma | 2021 | 29 |
39 | Emerging role of Hpo signaling and YAP in hepatocellular carcinoma | Journal of Hepatocellular Carcinoma | 2015 | 28 |
40 | Does alpha-fetoprotein contribute to the mortality and morbidity of human hepatocellular carcinoma? A commentary | Journal of Hepatocellular Carcinoma | 2016 | 28 |
41 | Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma – The Changing Tides | Journal of Hepatocellular Carcinoma | 2021 | 28 |
42 | Screening for hepatocellular carcinoma: patient selection and perspectives | Journal of Hepatocellular Carcinoma | 2017 | 27 |
43 | Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook | Journal of Hepatocellular Carcinoma | 2022 | 27 |
44 | c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma | Journal of Hepatocellular Carcinoma | 2015 | 26 |
45 | Surgical resection of localized hepatocellular carcinoma: patient selection and special consideration | Journal of Hepatocellular Carcinoma | 2017 | 26 |
46 | Needle track seeding after radiofrequency ablation for hepatocellular carcinoma: prevalence, impact, and management challenge | Journal of Hepatocellular Carcinoma | 2017 | 26 |
47 | Peritumoral Dilation Radiomics of Gadoxetate Disodium-Enhanced MRI Excellently Predicts Early Recurrence of Hepatocellular Carcinoma without Macrovascular Invasion After Hepatectomy | Journal of Hepatocellular Carcinoma | 2021 | 26 |
48 | <p>Genetic Biomarkers For Hepatocellular Carcinoma In The Era Of Precision Medicine</p> | Journal of Hepatocellular Carcinoma | 2019 | 25 |
49 | <p>Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors</p> | Journal of Hepatocellular Carcinoma | 2020 | 25 |
50 | Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide | Journal of Hepatocellular Carcinoma | 2021 | 25 |